Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 6,990 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma Clear all
Completed No phase listed Observational

Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer

NCT02681120
View directory record Official record
Conditions
Breast Neoplasms, Obesity
Interventions
Biopsy, Blood draw, Mammogram, MRI
Procedure
Lead sponsor
Tarah J Ballinger, MD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 16, 2026, 2:27 AM EDT
Completed No phase listed Observational

Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)

NCT06830486
View directory record Official record
Conditions
Breast Cancer
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 16, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

NCT03122301
View directory record Official record
Conditions
Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions
Stellate Ganglion Block injection with bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 16, 2026, 2:27 AM EDT
Terminated No phase listed Observational

Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone

NCT03529565
View directory record Official record
Conditions
Bone Pain, Breast Carcinoma Metastatic in the Bone
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 16, 2026, 2:27 AM EDT
Terminated Not applicable Interventional Results available

Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women

NCT04067544
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Female, Gynecologic Cancer
Interventions
Acupuncture
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663
View directory record Official record
Conditions
Breast Cancer
Interventions
D-0502, palbociclib
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer

NCT00001193
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
high dose melphalan and autologous bone marrow transplantation
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 16, 2026, 2:27 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

NCT01849328
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Rauscher, Gregory E., M.D. PA
Individual
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 16, 2026, 2:27 AM EDT
Suspended Phase 2 Interventional

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

NCT06214793
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Taletrectinib
Drug
Lead sponsor
Megan Kruse, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

NCT03691493
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Palbociclib, Radiation Therapy, Tamoxifen
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 16, 2026, 2:27 AM EDT
Completed No phase listed Observational

Lung Inflammation and Lung Metastases From Breast Cancer

NCT01182519
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaire, blood draw and urine sample
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 16, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

Utility of a Mobile Application for Young Women With Breast Cancer

NCT07009093
View directory record Official record
Conditions
Breast Cancer, Cancer Distress
Interventions
Mighty Pro Application
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 16, 2026, 2:27 AM EDT
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 16, 2026, 2:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT03899792
View directory record Official record
Conditions
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

NCT03280836
View directory record Official record
Conditions
Breast Neoplasm, Physical Activity
Interventions
Exercise
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 16, 2026, 2:27 AM EDT
Terminated No phase listed Observational

Patient Registry: Partial Breast Irradiation

NCT01127971
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Aquatic Exercise Study for Breast Cancer Patients With Lymphedema

NCT00498771
View directory record Official record
Conditions
Lymphedema
Interventions
Aquatic Exercise arm
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 16, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

NCT05384119
View directory record Official record
Conditions
Breast Cancer
Interventions
TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib
Drug
Lead sponsor
Tvardi Therapeutics, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

NCT02366130
View directory record Official record
Conditions
Breast Cancer
Interventions
Ra-223 dichloride, Denosumab, Hormone Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 16, 2026, 2:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

NCT02297230
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Phase II ABT-888 With Cyclophosphamide

NCT01306032
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions
ABT-888, Cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Davis, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 16, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Cancer Family Caregivers' Knowledge and Communication About Care Options

NCT02616107
View directory record Official record
Conditions
Family Caregivers
Interventions
Managing Cancer Care: A Caregiver's Guide, Symptom Management Toolkit
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 110 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 16, 2026, 2:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer

NCT00590109
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood test, Questionnaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 16, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Goserelin, Tamoxifen 20 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 2:27 AM EDT